Physician profile
Brad E Snyder
NPI 1275565178
$14,877.54
in general payments reported to CMS, 2019-2025
14 companies · $36.72 in 2025
The $36.72 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $146 · 2021: $144 · 2022: $105 · 2023: $333 · 2024: $550 · 2025: $36.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505 · Gift: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $505.22 |
| Gift | $414.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,393.30 | 2019-2024 | |
| Allergan, INC. | $501.49 | 2019-2020 | |
| Davol INC. | $157.89 | 2019-2022 | |
| Ethicon US, LLC | $151.30 | 2019-2021 | |
| Teleflex LLC | $131.86 | 2023 | Quikclot |
| Novo Nordisk INC | $103.62 | 2023 | |
| W. L. Gore & Associates, INC. | $99.03 | 2019 | |
| Abbvie INC. | $97.95 | 2023 | Alloderm |
| Olympus America INC. | $89.86 | 2019 | |
| Covidien LP | $74.50 | 2020 | |
| Alcresta Therapeutics, INC. | $22.81 | 2025 | Relizorb |
| Apollo Endosurgery US INC | $21.59 | 2019 | |
| Integra Lifesciences Corporation | $18.43 | 2021 | |
| Tela Bio, INC. | $13.91 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.